M von Wolff1,2, T Bruckner3, T Strowitzki4, A Germeyer5,4. 1. Division of Gynaecological Endocrinology and Reproductive Medicine, Women's University Hospital, University of Berne, Effingerstrasse 102, 3010, Berne, Switzerland. Michael.vonWolff@insel.ch. 2. FertiPROTEKT, Marburg, Germany. Michael.vonWolff@insel.ch. 3. Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany. 4. Division of Gynaecological Endocrinology and Reproductive Medicine, Women's University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany. 5. FertiPROTEKT, Marburg, Germany.
Abstract
PURPOSE: To study if ovarian response is affected by the type of disease if fertility preservation is required. METHODS: A registry of the trinational fertility preservation network FertiPROTEKT including 992 patients aged 18-40 years undergoing ovarian stimulation and follicle aspiration for fertility preservation from 1/2007 until 3/2016 was analysed. The number of collected oocytes, days of stimulation, total gonadotropin dosage and gonadotropin dosage per day were evaluated. RESULTS: Total oocyte number was negatively correlated with increasing age (r = 0.237, p < 0.0001). Oocyte numbers were in women < 26 years 15.4 ± 8.8, 26-30 years 13.1 ± 8.5, 31-35 years 12.2 ± 7.7 and 36-40 years 9.9 ± 8.0. Age-adjusted oocyte numbers were not different in women with Hodgkin's lymphoma (12.6 ± 8.8), non-Hodgkin's lymphoma (12.4 ± 8.2), leukaemia (11.7 ± 8.2), sarcoma (11.8 ± 8.2), cerebral cancer (16.5 ± 8.1), gastrointestinal cancer (13.2 ± 8.1) gynaecological cancer (10.8 ± 8.2) and other types of malignancies (15.8 ± 8.1) apart from ovarian cancer with lower oocyte yield (7.3 ± 8.3, p < 0.001) compared to women with breast cancer (13.3 ± 8.8). The total gonadotropin dose used for stimulation was only elevated in Hodgkin's and non-Hodgkin's lymphoma compared to women with breast cancer (p < 0.05). Oocyte yield was lower in women with versus without ovarian cancer (p < 0.0001). CONCLUSIONS: As ovarian response is not affected by the type of cancer, ovarian stimulation can be performed with the same oocyte yield in different malignant diseases. However, oocyte yield is reduced if ovarian surgery is required and in older women.
PURPOSE: To study if ovarian response is affected by the type of disease if fertility preservation is required. METHODS: A registry of the trinational fertility preservation network FertiPROTEKT including 992 patients aged 18-40 years undergoing ovarian stimulation and follicle aspiration for fertility preservation from 1/2007 until 3/2016 was analysed. The number of collected oocytes, days of stimulation, total gonadotropin dosage and gonadotropin dosage per day were evaluated. RESULTS: Total oocyte number was negatively correlated with increasing age (r = 0.237, p < 0.0001). Oocyte numbers were in women < 26 years 15.4 ± 8.8, 26-30 years 13.1 ± 8.5, 31-35 years 12.2 ± 7.7 and 36-40 years 9.9 ± 8.0. Age-adjusted oocyte numbers were not different in women with Hodgkin's lymphoma (12.6 ± 8.8), non-Hodgkin's lymphoma (12.4 ± 8.2), leukaemia (11.7 ± 8.2), sarcoma (11.8 ± 8.2), cerebral cancer (16.5 ± 8.1), gastrointestinal cancer (13.2 ± 8.1) gynaecological cancer (10.8 ± 8.2) and other types of malignancies (15.8 ± 8.1) apart from ovarian cancer with lower oocyte yield (7.3 ± 8.3, p < 0.001) compared to women with breast cancer (13.3 ± 8.8). The total gonadotropin dose used for stimulation was only elevated in Hodgkin's and non-Hodgkin's lymphoma compared to women with breast cancer (p < 0.05). Oocyte yield was lower in women with versus without ovarian cancer (p < 0.0001). CONCLUSIONS: As ovarian response is not affected by the type of cancer, ovarian stimulation can be performed with the same oocyte yield in different malignant diseases. However, oocyte yield is reduced if ovarian surgery is required and in older women.
Authors: Barbara Lawrenz; Julia Jauckus; Markus Kupka; Thomas Strowitzki; Michael von Wolff Journal: Fertil Steril Date: 2010-08-03 Impact factor: 7.329
Authors: Cosima Huober-Zeeb; Barbara Lawrenz; Roxana M Popovici; Thomas Strowitzki; Ariane Germeyer; Petra Stute; Michael von Wolff Journal: Fertil Steril Date: 2010-08-24 Impact factor: 7.329
Authors: L Caponecchia; G Cimino; R Sacchetto; C Fiori; A Sebastianelli; P Salacone; I Marcucci; S Tomassini; R Rago Journal: Andrologia Date: 2015-07-14 Impact factor: 2.775
Authors: Lauren N C Johnson; Katherine E Dillon; Mary D Sammel; Brenda L Efymow; Monica A Mainigi; Anuja Dokras; Clarisa R Gracia Journal: Reprod Biomed Online Date: 2013-01-19 Impact factor: 3.828
Authors: Molly M Quinn; Hakan Cakmak; Joseph M Letourneau; Marcelle I Cedars; Mitchell P Rosen Journal: Hum Reprod Date: 2017-03-01 Impact factor: 6.918
Authors: Daniel Bodri; Juan José Guillén; Anna Galindo; Daniel Mataró; Aïda Pujol; Oriol Coll Journal: Fertil Steril Date: 2008-03-25 Impact factor: 7.329